Allysa Saggese, NP, a nurse practitioner in liver disease and transplantation at Weill Cornell Medicine, reflects on recent developments in the PBC treatment landscape, including the approvals of 2 new second-line treatment options with elafibranor and seladelpar.

She emphasizes the importance of having second-line therapies in PBC, citing the need to have something to offer patients who may be intolerant to ursodeoxycholic acid, the standard first-line therapy, and/or obeticholic acid, what was previously the only FDA-apprvoed second-line therapy.

“One thing that I keep learning through discussing all of the medications, treating my patients, and being a part of the trials is that we might need to be more conscious of how we are talking about PBC symptoms,” Saggese said, describing her own experiences inquiring about itch and the importance of making patients aware that it may be a symptom or side effect of PBC. “We need to make sure we're providing the most comprehensive kind of care for these patients.”

#Hepatology #PBC #PrimaryBiliaryCholangitis #Treatment

0 Comments

Up next

Autoplay

What Are the Common Side Effects of Breo Ellipta for COPD? | COPD Care Collective

2 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

Updates in Primary Biliary Cholangitis Care

Up next

Language